Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic agents for pancreatic exocrine function

a technology of pancreatic exocrine function and diagnostic agent, which is applied in the field of compounds, can solve the problems of increased pancreatic exocrine enzymes in the blood, inability to be used repeatedly or for screening, and inability to meet the needs of patients,

Inactive Publication Date: 2005-01-27
KOHNO TADASHI +4
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The subject matters of the present invention are as follows. (1) A 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose. (2) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to (1), which is hydrolyzed with α-amylase. (3) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to (2), which is not hydrolyzed with α-glucosidase. (4) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to any one of (1), to (3), wherein at least one sugar molecule constituting the oligosaccharide or polysaccharide is 13C - labeled. (5) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to any one of (1) to (3), wherein at least one sugar molecule constituting the oligosaccharide or polysaccharide is modified with at least one 13C-labeled modifying group. (6) The 13C-labeled oligosaccharide or polysaccharide or seal thereof according to any one of (1) to (5), which is a linear or branched oligosaccharide or polysaccharide. (7) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to any one of (1) to (5), which is a cyclic oligosaccharide or polysaccharide. (8) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to (6), which is modified at the non-reducing terminal. (9) The 13C-labeled oligosaccharide or polysaccharide or salt thereof according to (1), which is a 13C-cyclodextrin or β-galactosyl-13C-maltooligosaccharide. (10) A derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof according to any one of (1) to (9). (11) A 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule. (12) The inclusion complex or salt thereof according to (11), wherein the host molecule is 13C-labeled. (13) The inclusion complex or salt thereof according to (11), wherein the guest molecule is 13C-labeled. (14) The inclusion complex or salt thereof according to any one of (11) to (13), wherein the guest molecule is selected from the group consisting of oligosaccharides, amino acids, peptides, organic acids, fatty acids, fatty acid glycerides, vitamins, catechins, carotinoids, flavonoids and cholesterol. (15) The inclusion complex or salt thereof according to (14), wherein the guest molecule is selected from the group consisting of 13C-phenylalanine, benzoylphenylalanyl-13C-leucine and benzoylphenylalanyl-13C-leucine methyl ester. (16) A diagnostic agent for pancreatic exocrine function comprising a 13C- or 14C-labeled oligosaccharide or polysaccharide or a salt thereof or a derivative thereof other than 13C-starch. (17) The diagnostic agent for pancreatic exocrine function according to (16), wherein the 13C- or 14C-labeled oligosaccharide or polysaccharide or salt thereof or derivative thereof is hydrolyzed with α-amylase. (18) The diagnostic agent for pancreatic exocrine function according to (17) wherein the 13C- or 14C-labeled oligosaccharide or polysaccharide or salt thereof or derivative thereof is not hydrolyzed with α-glucosidase. (19) The diagnostic agent for pancreatic exocrine function according to any one of (16) to (18), wherein the 13C- or 14C-labeled oligosaccharide or polysaccharide is a linear or branched oligosaccharide or polysaccharide. (20) The diagnostic agent for pancreatic exocrine function according to (19), wherein the 13C- or 14C-labeled oligosaccharide or polysaccharide is modified at the non-reducing terminal. (21) The diagnostic agent for pancreatic exocrine function according to any one of (16) to (18), wherein the 13C- or 14C-labeled oligosaccharide or polysaccharide is a cyclic oligosaccharide or polysacchari

Problems solved by technology

However, this method can not be used repeatedly or used for screening because of the very strong stress caused on the subjects.
Further, since this method requires fluoroscopic tube placement during the collection of the duodenal juice, there is the problem of X ray exposure.
However, the increase of the pancreatic exocrine enzymes in the blood is only observed at the initial stage of acute pancreatitis or at the recrudescent stage of chronic pancreatitis and does not always reflect the ability of the pancreas to secrete pancreatic exocrine enzymes.
However, this method requires a long time to carry out the test and therefore can not often be performed on outpatients and is not suitable in physical examinations.
However, any 13C-labeled oligosaccharide or polysaccharide other than 13C-labeled starch has not yet been studied.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic agents for pancreatic exocrine function
  • Diagnostic agents for pancreatic exocrine function
  • Diagnostic agents for pancreatic exocrine function

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 13C-labeled Cyclodextrin

13C-labeled starch (Chlorella Industry, Algal Starch (water-soluble), Lot No. 8031,S, U-13C:98.6 atom %, Starch Content: 93.5%) was dissolved in 50 mM acetate buffer (pH 5.4) at a concentration of 5% (w / v) and 100 Units of cyclomaltodextrin glucanotransferase (Hayashibara) was added thereto and reacted at 40° C. for 24 hours. After the enzyme was inactivated with the treatment at 100° C. for 15 minutes, glucoamylase was added and reacted at 40° C. for 1 hour to decompose components other than 13C-labeled cyclodextrin into glucose. After the reaction was completed, the reaction mixture was treated at 100° C. for 15 minutes to inactivate the glucoamylase.

The solution was applied to a carbon column (2.5 cm×25 cm) and the column was washed with 500 ml of water. A 15% ethanol solution and a 40% ethanol solution were sequentially applied to recover the 13C-labeled cyclodextrin in the 40% ethanol solution eluted fractions. The resulting 13C-labele...

example 2

13C-labeled Cyclodextrin Breath Test

13C-labeled cyclodextrin breath test was carried out wherein 13C-labeled cyclodextrin prepared in Example 1 was orally administered to chronic pancreatitis and control rats and the time course of the 13C concentration in the exhaled CO2 after the administration was measured.

According to Mundlos et al. (Mundlos et al., Pancreas, 1:29 (1986)), the chronic pancreatitis rats were prepared by injecting oleic acid into the pancreatic duct of Wistar male rats of 5 weeks old and kept for 3 weeks. Rats in which midline incision was made on the abdomen were used as the control.

The chronic pancreatitis and control rats of 8 weeks old, which fasted overnight, were fixed without anesthesia in a rat holder for a microwave irradiation apparatus. The breath was collected at a rate of about 100 to 300 ml / min using a stroke pump (Variable Stroke Pump VS-500, Shibata Kagaku Kogyo) and introduced directly to a flow cell of a 13CO2 analyzer EX-130S (Nihon Bunko) ...

example 3

Preparation of C-labeled Galactosylmaltohexaose

13 C-labeled starch (Chlorella Industry, 4.65 g) was dissolved in a 50 mM acetate buffer (pH 5.4) at a concentration of 0.5% (w / v) and 186 Units of cyclomaltodextrin glucanotransferase (Hayashibara) was added thereto and reacted at 40° C. for 2 hours and 20 minutes. The enzyme was inactivated with the treatment at 95° C. for 15 minutes and the product was purified by Sephadex G-25. This procedure was repeated 4 times to yield 4.39 g of 13C -α-cyclodextrin (yield 23.6%).

Pyridine (200 mL) was added to 4.39 g of the resulting 13C-α-cyclodextrin and ice cooled. Acetic anhydride (100 mL) was added thereto. After 30 minutes, the reaction mixture was removed out of the ice bath and then stirred at room temperature for 36 hours. To the residue obtained by concentration under reduced pressure, toluene was added and azeotropically distilled. This procedure was repeated three times. Ethyl acetate and water were added to the residue to extract....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C -amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel compounds useful as diagnostic agents for pancreatic exocrine function and their use. 2. Background of the Invention “Pancreatic exocrine function tests” are useful for the diagnosis of pancreatic diseases such as chronic and acute pancreatitis and pancreatic cancer. They are also useful to assess the condition and prognosis of patients and to control the medication: The general descriptions are found in Arvanitakis and Cooke, Gastroenterology, 74:932 (1978); Niederau and Grendell, Gastroenterology, 88:1973 (1985); Goldberg, Bull. Mol. Biol. Med., 15:1 (1990); Lankisch, Int. J. Pancreatology, 14:9 (1993); Bank and Chow, Gastroenterologist, 2:224 (1994); and Steer et al., New Eng. J. Med., 332:1482 (1995) At present, “Gold standard” of the pancreatic exocrine function test involves inserting a tube through the mouth to the duodenum to collect the duodenal juice. Now, the secretin test is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K49/06A61K49/18A61K51/04A61K51/06A61K51/12C08B37/00
CPCA61K49/06A61K49/10A61K49/12A61K49/1815A61K49/189C08B37/00A61K51/06A61K51/1206A61K51/1268B82Y5/00A61K51/0491A61K49/126C07H3/06
Inventor KOHNO, TADASHIHOSOI, ISABUROOHSHIMA, JUNKOSHIBATA, KUNIHIKOITO, ASUKA
Owner KOHNO TADASHI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com